Myriad Genetics Inc
XHAM:MYD

Watchlist Manager
Myriad Genetics Inc Logo
Myriad Genetics Inc
XHAM:MYD
Watchlist
Price: 5.45 EUR 3.81% Market Closed
Market Cap: 490m EUR

Myriad Genetics Inc
Revenue

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Myriad Genetics Inc
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Myriad Genetics Inc
NASDAQ:MYGN
Revenue
$825.3m
CAGR 3-Years
8%
CAGR 5-Years
7%
CAGR 10-Years
1%
Abbvie Inc
NYSE:ABBV
Revenue
$59.6B
CAGR 3-Years
1%
CAGR 5-Years
8%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Revenue
$29.1B
CAGR 3-Years
2%
CAGR 5-Years
5%
CAGR 10-Years
-1%
Amgen Inc
NASDAQ:AMGN
Revenue
$36B
CAGR 3-Years
11%
CAGR 5-Years
8%
CAGR 10-Years
5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Revenue
$11.7B
CAGR 3-Years
10%
CAGR 5-Years
14%
CAGR 10-Years
31%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Revenue
$14.2B
CAGR 3-Years
1%
CAGR 5-Years
12%
CAGR 10-Years
14%
No Stocks Found

Myriad Genetics Inc
Glance View

Market Cap
507.4m EUR
Industry
Biotechnology

Nestled at the crossroads of healthcare innovation and genetic science, Myriad Genetics Inc. has been a pioneering force in molecular diagnostics for over three decades. Founded in 1991 and headquartered in Salt Lake City, Utah, the company carved out its niche by focusing on predictive medicine—an area that seeks to forecast disease risk based on genetic predispositions. At the heart of Myriad's operations is its robust arsenal of genetic tests that identify individuals' risk for various conditions, including cancer, cardiovascular illnesses, and other hereditary disorders. This approach not only aids early intervention and personalized treatment plans but also empowers patients with crucial information about their genetic backgrounds. Myriad's business model orbits around the research, development, and commercialization of these high-impact diagnostic tests. Revenue streams flow primarily from the sale of its flagship products, which include the BRACAnalysis CDx test for assessing breast and ovarian cancer risk and various other hereditary cancer tests that evaluate susceptibility to prostate and colorectal cancers. Further, Myriad advances its impact through collaborations with healthcare providers, folding clinical research findings into broader medical practice. In a world where healthcare is increasingly leaning towards precision medicine, Myriad Genetics stands as a testament to the value of science-led business strategies, sustaining its growth through a clear focus on marrying advanced genomic knowledge with accessible and actionable clinical applications.

MYD Intrinsic Value
14.39 EUR
Undervaluation 62%
Intrinsic Value
Price

See Also

What is Myriad Genetics Inc's Revenue?
Revenue
825.3m USD

Based on the financial report for Sep 30, 2025, Myriad Genetics Inc's Revenue amounts to 825.3m USD.

What is Myriad Genetics Inc's Revenue growth rate?
Revenue CAGR 10Y
1%

Over the last year, the Revenue growth was 0%. The average annual Revenue growth rates for Myriad Genetics Inc have been 8% over the past three years , 7% over the past five years , and 1% over the past ten years .

Back to Top